ZIOPHARM ONCOLOGY 8-K 2018
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): March 12, 2018
ZIOPHARM Oncology, Inc.
(Exact Name of Registrant as Specified in Charter)
(Registrants telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act (17 CFR 230.405) or Rule 12b-2 of the Exchange Act (17 CFR 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
(b) On March 12, 2018, Dr. Michael Weiser resigned from the board of directors, or the Board, of Ziopharm Oncology, Inc., or the Company, including all committees thereof, effective immediately.
Effective March 12, 2018, the Board appointed James Cannon to serve on the Boards compensation committee. Following such appointment, the members of the compensation committee are Scott Tarriff, who will serve as the committees chairman, Dr. Murray Brennan and James Cannon.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.